GSK Articles
Barriers to overcome in lupus drug development
22 July 2012
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with Human Genome?
16 July 2012
GlaxoSmithKline to plead guilty and pay record $3 billion to resolve US fraud allegations
3 July 2012
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada
10 June 2012
FDA clears GlaxoSmithKline's Horizant for PHN
8 June 2012
More news from ASCO meeting
5 June 2012
GlaxoSmithKline files for new eltrombopag indications in EU and USA; gains rights to derma products
31 May 2012
News briefs: Genmab/GSK, Gilead and Mylan
24 May 2012
News briefs: GlaxoSmithKline and Bayer
24 May 2012
GlaxoSmithKline buys full control of Cellzome
16 May 2012
US FDA backs new indications for Votrient and Afinitor
29 April 2012
UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin
27 April 2012
Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus
26 April 2012
Price and Preferred Tier main consideration of US physicians in intent to prescribe COPD drugs
12 April 2012
GlaxoSmithKline links with Japan's Chiome on MAbs
10 April 2012
GSK settles with Genentech over ofatumumab patents
28 March 2012
FDA panel backs GlaxoSmithKline sarcoma drug Votrient
21 March 2012
Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers
20 March 2012
GlaxoSmithKline off loads more OTC brands
15 March 2012
Epistem in fibrosis research deal with GlaxoSmithKline
13 March 2012
GSK and Daiichi Sankyo set up Japanese vaccines JV
2 March 2012
GSK inks $300m rare diseases alliance with Angiochem
28 February 2012
GSK boss accuses UK government of blocking new drugs to save money
27 February 2012
No proof of added benefit for GlaxoSmithKline’s Trobalt, says IQWiG
27 February 2012
Mylan gets tentative FDA approval for generic Epzicom
23 February 2012
Nine news Rx drugs added to Australian PBS listings
22 February 2012
GSK exercises option for Galapagos drug candidates
21 February 2012
EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri
20 February 2012
GSK and Novartis withdraw EU extended use applications for Tyverb and Fluad, respectively
16 February 2012
NICE views breast cancer drugs from GSK and Roche too expensive
14 February 2012
GlaxoSmithKline pauses four UTI drug trials
7 February 2012
Astex to return epigenetics project to GSK
17 January 2012
GlaxoSmithKline challenges Argentina court ruling
12 January 2012
US ANDAs filed for generic Beyaz, Isentress and Epivir
12 January 2012
GSK and Theravance to file COPD/asthma drug
10 January 2012
Milestone for ChemoCentryx as GSK exercises license option
6 January 2012
Progress toward a genital herpes vaccine
5 January 2012
Covis acquires US rights for GlaxoSmithKline brands
22 December 2011
SEC says GSK unit CEO defrauded shareholders
14 December 2011
Benlysta gaining bigger US market share
13 December 2011
News briefs from breast cancer meeting
12 December 2011
Robust growth forecast for renal cell carcinoma market
11 December 2011
Pozen sells future royalty rights to Treximet for $75 million
28 November 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
